Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The national surgical adjuvant study of breast cancer 02

Oncology

Volumn 82, Issue 3, 2012, Pages 131-138

  Ohsumi, Shozo ^a   Shimozuma, Kojiro ^b   Ohashi, Yasuo ^c   Takeuchi, Ayano ^c   Suemasu, Kimito ^d   Kuranami, Masaru ^e   Ohno, Shinji ^f   Watanabe, Toru ^g  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Arche Clinic   (Japan)

^e KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g Hamamatsu Oncology Center   (Japan)

Author keywords

Adjuvant chemotherapy; Breast cancer; Chemotherapy induced edema; Quality of life; Taxane

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ADULT; AGED; ANASARCA; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER ADJUVANT THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOOT EDEMA; FUNCTIONAL ASSESSMENT; HAND EDEMA; HUMAN; JAPANESE; LEG EDEMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EDEMA; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TAXOIDS;

EID: 84862792772     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000336480     Document Type: Article

References (31)

1. Hery C, Ferlay J, Boniol M, Autier P: Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2008; 19: 1009-1018. (Pubitemid 351627322)
2. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332: 901-906.
3. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-2658. (Pubitemid 28363028)
4. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
5. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S: Taxanebased combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53.
6. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 1995; 13: 2643-2655.
7. Behar A, Pujade-Lauraine E, Maurel A, Brun MD, Chauvin FF, Feuihade de Chauvin F, Oulid-Aissa D, Hille D: The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 1997; 43: 653-658. (Pubitemid 27283577)
8. Semb KA, Aamdal S, Oian P: Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16: 3426-3432. (Pubitemid 28481642)
9. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM: Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14: 422-428.
10. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15: 3149-3155. (Pubitemid 27377507)
11. Ohsumi S, Sunada Y: Techniques for the neurological examination of taxane-induced neuropathy. Breast Cancer 2004; 11: 86-91.
12. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006; 24: 1633-1642. (Pubitemid 46638788)
13. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH: Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 2009; 17: 1483-1491.
14. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551.
15. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671. (Pubitemid 351549913)
16. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol 2008; 26: 1642-1649.
17. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK: Health-related qualityof-life assessments and patient-physician communication: a randomized controlled trial. JAMA 2002; 288: 3027-3034. (Pubitemid 35471165)
18. Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Iwata H, Mukai H, Tanaka S, Yamaguchi T, Ohashi Y: Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxane with 8-cycle taxane as adjuvant therapy for nodepositive breast cancer: results of N-SASBC02 trial (abstract 516). J Clin Oncol 2009; 27(suppl):15s.
19. Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y: Docetaxel is superior to paclitaxel given every three weeks in postoperative patients with node-positive breast cancer: results of the final analyses of the NSAS-BC (National Surgical Adjuvant Study of Breast Cancer) 02 trial from Japan. Cancer Res 2011; 71: 140s-141s.
20. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997; 15: 974-986. (Pubitemid 27106280)
21. Taira N, Shimozuma K, Shiroiwa T, Ohsumi S, Kuroi K, Saji S, Saito M, Iha S, Watanabe T, Katsumata N: Association among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Res Treat 2011; 128: 735-747.
22. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA: Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACTtaxane). Cancer 2003; 98: 822-831. (Pubitemid 36959280)
23. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Siberman M, Yellen SB, Winicour P, Brannon J: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579. (Pubitemid 23071057)
24. Fumimoto H, Kobayashi K, Chang CH, Eremenco S, Fujiki Y, Uemura S, Ohashi Y, Kudoh S: Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res 2001; 10: 701-709. (Pubitemid 34145321)
25. FACIT Translation Project Procedures and Guidelines. FAICT Manual, version 4, Center on Outcomes, Research and Education (CORE). Evanston, Evanston Northwestern Healthcare and Northwestern University, 1997.
26. Erickson VS, Pearson ML, Ganz PA, Adam J, Kahn KL: Arm edema in breast cancer patients. J Natl Cancer Inst 2001; 93: 96-111. (Pubitemid 32111987)
27. Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR: Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. J Clin Oncol 2008; 26: 5689-5696.
28. Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Demichele A, Solin LJ: Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 2009; 27: 390-397.
29. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C: Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med 2005; 352: 2302-2313. (Pubitemid 40740554)
30. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354. (Pubitemid 29368232)
31. Lette J: A simple and innovative device to measure arm volume at home for patients with lymphedema after breast cancer. J Clin Oncol 2006; 24: 5434-5440. (Pubitemid 46623177)